Alurar rigakafin cutar sankarar huhu bayan ci gaba da cutar sankarar huhu ta ba da damar ciwace-ciwace ta ci gaba

Alurar rigakafin cutar sankarar huhu bayan ci gaba da cutar sankarar huhu ta ba da damar ciwace-ciwace ta ci gaba. Haɗa tare da mu don mafi kyawun maganin ciwon huhu a Indiya tare da mafi kyawun likitoci don maganin ciwon huhu na huhu.

Share Wannan Wallafa

 

A watan Disambar 2007, Malama 54, wacce ta yi fama da cutar ta rashin lafiya tsawon watanni 2, ta rage kiba, rashin cin abinci, kuma tana da ciwon kashi. A CT hoton kirji ya saukar da 9 cm x 5.8 cm x 7.2 cm "babba, an gyara shi, an inganta shi iri-iri" a cikin hagu zuwa ƙasan huhu. Bugu da kari, an sami wani karamin rauni mai kama da allura a cikin babba na hagu na sama.

Daga baya, biopsy ya tabbatar da cutarwa, matsakaiciyar rarrabewar huhu mai cutar sankarau. A CT dubawa ya nuna shigar tsokoki na bangon kirji kuma ya sami metastasized. Duban kashinta ba ya da kyau (babu metastases). Saboda haka, an gano ta da matakin T4N1M0-IIIb mara karamin tantanin halitta kwayar cutar huhu.

A cikin watanni 3, an bi da Ms. M tare da paclitaxel (260 MG) da carboplatin (415 MG) don hawan hawan 3. Wannan yana raguwa da tumo zuwa 7 cm x 6 cm x 5 cm. Daga baya, an yi maganin chemoradiotherapy a layi daya tare da hawan 2 na cisplatin (50 MG) da 60 Gy na radiation.

Watanni biyu bayan kammala aikin chemoradiotherapy, Ms. M ta sami labarin cewa akwai gwajin asibiti na huhu. maganin ciwon daji kuma sun yanke shawarar karɓar maganin CIMAvax bayan yin tunani game da shi.

80% na mutanen da suka karɓi maganin cyclophosphamide kafin allurar CIMAvax sun nuna wasu ayyukan anti-EGF. Alurar riga kafi a shafuka da yawa zai ƙara haɓaka tasiri.

Wani CT scan na farko ya nuna raunin 3 cm x 3 cm a cikin ƙananan lobe (Figure 1). Raunin lobe na hagu na hagu bai wuce santimita 1 a diamita ba, kuma zubar da jini a cikin gida ya kasance na biyu zuwa aikin rediyo.

Bayan watanni 3 na maganin CIMAvax na maganin rigakafin huhu, kumburin ya ragu zuwa 2 cm x 2.1 cm

Zuwa watanni 6 na jinya, ciwon ya yanke daga asalinsa da kashi 30% zuwa 1.5 cm x 2.3 cm kafin daidaitawa. A wannan lokacin, gurɓataccen muryarta na ci gaba da raguwa, kuma lymph nodes na gida sun zama ƙarami.

Yayin harbi 16 na farko, Madam M ba ta sami wata illa ba. A cikin 'yan mintuna kaɗan na allurar ta 17, jinƙan kugu ya "karu" kuma ana ɗauka amsar rigakafi mai alaƙa da Mataki na 3. Kwayar cututtukan sun lafa bayan minti 10 na magani tare da 10 mg na chlorpheniramine, 200 mg na hydrocortisone da 50 mg na tramadol.

Daga baya, ta yanke shawarar dakatar da magani tare da rigakafin CIMAvax. Anyi hoton CT na kirji watanni uku bayan dakatar da jiyya (watanni 18 bayan fara maganin CIMAvax). Watanni shida sun shude tun bayan binciken ta na karshe, kuma babu wani “gagarumin canji” a girman ƙari (Hoto na 3), kuma yanayinta ya kasance mai karko.

A bin bayan-28 na ƙarshe bayan dakatar da allurar rigakafin-FNM mata na cikin ƙoshin lafiya da lafiya da kwanciyar hankali. Matsayinta na ECOG ya kasance a 0 (mafi kyau). A wannan lokacin, ta rayu tsawon watanni 48 tun lokacin da aka gano ta kuma yanayinta ya daidaita.

Madam M's maganin huhu na huhu An amince da shi don tallatawa a Cuba a cikin 2008 don kulawa da mataki na IIIB-IV marasa ciwon ciwon huhu na huhu (NSCLC). Wannan shi ne rajista na farko na rigakafin warkewa a Cuba da kuma rajista na farko na rigakafin cutar kansar huhu a duniya.

 

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS
Cancer

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS

Lutetium Lu 177 dotatate, magani mai ban sha'awa, kwanan nan ya sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) ga marasa lafiya na yara, wanda ke nuna gagarumin ci gaba a cikin ilimin cututtukan cututtukan yara. Wannan amincewar tana wakiltar alamar bege ga yara masu fama da ciwace-ciwacen ƙwayoyin cuta na neuroendocrine (NETs), nau'in ciwon daji da ba kasafai ba amma ƙalubale wanda galibi ke tabbatar da juriya ga hanyoyin warkewa na al'ada.

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.
Ciwon daji na bladder

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.

“Nogapendekin Alfa Inbakicept-PMLN, wani labari na rigakafi, yana nuna alƙawarin magance cutar kansar mafitsara idan aka haɗa shi da maganin BCG. Wannan sabuwar dabarar ta shafi takamaiman alamomin cutar kansa yayin da ake ba da amsa ga tsarin rigakafi, yana haɓaka ingancin jiyya na gargajiya kamar BCG. Gwajin gwaje-gwaje na asibiti suna bayyana sakamako masu ƙarfafawa, yana nuna ingantattun sakamakon haƙuri da yuwuwar ci gaba a cikin sarrafa kansar mafitsara. Haɗin kai tsakanin Nogapendekin Alfa Inbakicept-PMLN da BCG yana sanar da sabon zamani a cikin maganin cutar kansar mafitsara."

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton